

(19)



Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11)

EP 1 074 620 A1

(12)

## EUROPEAN PATENT APPLICATION

(43) Date of publication:  
**07.02.2001 Bulletin 2001/06**

(51) Int Cl.7: **C12N 15/12, C07K 14/495,  
A61K 38/18**

(21) Application number: **99115613.4**

(22) Date of filing: **06.08.1999**

(84) Designated Contracting States:  
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU  
MC NL PT SE**  
Designated Extension States:  
**AL LT LV MK RO SI**

(71) Applicant: **HyGene AG,  
c/o Mäder + Baumgartner Treuhand AG  
8121 Neuhausen am Rheinfall (CH)**

(72) Inventor: **The designation of the inventor has not  
yet been filed**

(74) Representative:  
**Böhm, Brigitte, Dipl.-Chem. Dr. et al  
Weickmann & Weickmann  
Patentanwälte  
Postfach 86 08 20  
81635 München (DE)**

### (54) Monomeric protein of the TGF-beta family

(57) The present invention is concerned with proteins selected from the members of the TGF- $\beta$  superfamily, which are monomeric due to substitution or deletion of a cysteine which is responsible for dimer formation.

The invention is also concerned with nucleic acids,

encoding such monomeric proteins, vectors or host cells containing the nucleic acids as well as with pharmaceutical compositions comprising the proteins or nucleic acids encoding the proteins. The pharmaceutical compositions can be applied advantageously for all indications for which the respective dimeric proteins are useful.

**Description**

**[0001]** The present invention concerns a biologically active protein from the TGF- $\beta$  superfamily, wherein this protein remains in monomeric form due to substitution or deletion of a cysteine which is responsible for the dimerization in the wild-type protein. Further the invention concerns a nucleic acid, which codes for a protein according to the invention, an expression vector containing such nucleic acid and a host cell, containing a corresponding nucleic acid or an expression vector, said nucleic acid being suitable for the expression of the protein. The invention also concerns a pharmaceutical composition containing the protein according to the invention or a nucleic acid coding therefor. The use of the pharmaceutical composition according to the invention concerns the prevention or treatment of all conditions which can also be treated with the dimeric form of the corresponding protein.

**[0002]** Many growth factors from the TGF- $\beta$  superfamily (Kingsley, Genes and Development 8, 133-146 (1994) as well as the references cited therein) are relevant for a wide range of medical treatment methods and applications which in particular concern promotion of cell proliferation and tissue formation, including wound healing and tissue reproduction. Such growth factors in particular comprise members of the TGF- $\beta$  (transforming growth factor, cf. e.g. Roberts and Sporn, Handbook of Experimental Pharmacology 95 (1990), page 419-472, editors: Sporn and Roberts), the DVR-group (Hötten et al., Biochem. Biophys. Res. Comm. 206 (1995), page 608-613 and further literature cited therein) including BMPs (bone morphogenetic protein, cf. e.g. Rosen and Thies, Growth Factors in Perinatal Development (1993), page 39-58, editors: Tsang, Lemons and Balistreri) and GDFs (growth differentiation factors), the inhibin/activin (cf. e.g. Vale et al., The Physiology of Reproduction, second edition (1994), page 1861-1878, editors: Knobil and Neill) and the GDNF protein family (Rosenthal, Neuron 22 (1999), page 201-203; Airaksinen et al. Mol Cell Neurosci 13 (1999), page 313-325). Although the members of the TGF- $\beta$  superfamily show high amino acid homologies in the mature part of the protein, in particular 7 conserved cysteines, they show considerable variations in their exact functions. Often individual growth factors of these families exhibit a plurality of functions at the same time, so that their application is of interest in various medical indications. Some of these multifunctional proteins also have survival promoting effects on neurons in addition to functions such as e.g. regulation of the proliferation and differentiation in many cell types (Roberts and Sporn, supra; Sakurai et al., J. Biol. Chem. 269 (1994), page 14118-14122). Thus e.g. trophic effects on embryonic motoric and sensory neurons were demonstrated for TGF- $\beta$  in vitro (Martinou et al., Devl. Brain Res. 52, page 175-181 (1990) and Chalazonitis et al., Dev. Biol. 152, page 121-132 (1992)). In addition, effects promoting survival are shown for dopaminergic neurons of the mid-brain for the proteins TGF- $\beta$ -1, -2, -3, activin A and GDNF (glial cell line-derived neurotrophic factor), a protein which has structural similarities to TGF- $\beta$  superfamily members, these effects being not mediated via astrocytes (Kriegstein et al., EMBO J. 14, page 736-742 (1995)).

**[0003]** Interesting members of the TGF- $\beta$  superfamily or active variants thereof comprise the TGF- $\beta$  proteins like TGF- $\beta$ 1, TGF- $\beta$ 2, TGF- $\beta$ 3, TGF- $\beta$ 4, TGF- $\beta$ 5 (U.S. 5,284,763; EP 0376785; U.S. 4,886,747; DNA 7 (1988), page 1-8), EMBO J. 7 (1988), page 3737-3743), Mol. Endo. 2 (1988), page 1186-1195), J. Biol. Chem. 265 (1990), page 1089-1093), OP1, OP2 and OP3 proteins (U.S. 5,011,691, U.S. 5,652,337, WO 91/05802) as well as BMP2, BMP3, BMP4 (WO 88/00205, U.S. 5,013,649 and WO 89/10409, Science 242 (1988), page 1528-1534), BMP5, BMP6 and BMP-7 (OP1) (Proc. Natl. Acad. Sci. 87 (1990), page 9841-9847, WO 90/11366), BMP8 (OP2) (WO 91/18098), BMP9 (WO 93/00432), BMP10 (WO 94/26893), BMP11 (WO 94/26892), BMP12 (WO 95/16035), BMP13 (WO 95/16035), BMP15 (WO 96/36710), BMP16 (WO 98/12322), BMP3b (Biochem. Biophys. Res. Comm. 219 (1996), page 656-662), GDF1 (WO 92/00382 and Proc. Natl. Acad. Sci. 88 (1991), page 4250-4254), GDF8 (WO 94/21681), GDF10 (WO 95/10539), GDF11 (WO 96/01845), GDF5 (CDMP1, MP52) (WO 95/04819; WO 96/01316; WO 94/15949, WO 96/14335 and WO 93/16099 and Nature 368 (1994), page 639-643), GDF6 (CDMP2, BMP13) (WO 95/01801, WO 96/14335 and WO 95/16035), GDF7 (CDMP3, BMP12) (WO 95/01802 and WO 95/10635), GDF14 (WO 97/36926), GDF15 (WO 99/06445), GDF16 (WO 99/06556), 60A (Proc. Natl. Acad. Sci. 88 (1991), page 9214-9218), DPP (Nature 325 (1987), page 81-84), Vgr-1 (Proc. Natl. Acad. Sci. 86 (1989), page 4554-4558) Vg-1, (Cell 51 (1987), page 861-867), dorsalin (Cell 73 (1993), page 687-702), MIS (Cell 45 (1986), page 685-698), pCL13 (WO 97/00958), BIP (WO 94/01557), inhibin  $\alpha$ , activin  $\beta$ A and activin  $\beta$ B (EP 0222491), activin  $\beta$ C (MP121) (WO 96/01316), activin  $\beta$ E and GDF12 (WO 96/02559 and WO 98/22492), activin  $\beta$ D (Biochem. Biophys. Res. Comm. 210 (1995), page 581-588), GDNF (Science 260 (1993), page 1130-1132, WO 93/06116), Neurturin (Nature 384 (1996), page 467-470), Persephin (Neuron 20 (1998), page 245-253, WO 97/33911), Artemin (Neuron 21 (1998), page 1291-1302), Mic-1 (Proc. Natl. Acad. Sci USA 94 (1997), page 11514-11519), Univin (Dev. Biol. 166 (1994), page 149-158), ADMP (Development 121 (1995), page 4293-4301), Nodal (Nature 361 (1993), page 543-547), Screw (Genes Dev. 8 (1994), page 2588-2601). Other useful proteins include biologically active biosynthetic constructs including biosynthetic proteins designed using sequences from two or more known morphogenetic proteins. Examples of biosynthetic constructs are disclosed in U.S. 5,011,691 (e.g. COP-1, COP-3, COP-4, COP-5, COP-7 and COP-16). The disclosure of the cited publications including patents or patent applications are incorporated herein by reference.

**[0004]** The occurrence of proteins of the TGF- $\beta$  superfamily in various tissues and development stages corresponds with differences with regard to their exact functions as well as target sites, life span, requirements for auxiliary

factors, necessary cellular physiological environment and/or resistance to degradation.

[0005] The proteins of the TGF- $\beta$  superfamily exist as homodimers or heterodimers having a single disulfide bond. This disulfide bond is mediated by a specific and in most of the proteins conserved cysteine residue of the respective monomers. Up to now it was considered as indispensable for the biological activity that the protein is present in its dimeric form. Several publications indicated that biological activity can only be obtained for dimeric proteins and it was speculated that this dimer formation is important for further polymer formation of two or more dimers to achieve inter-cellular signal transmission by simultaneous binding to type I and type II receptors for the TGF- $\beta$  superfamily proteins on cells. It was assumed that only this simultaneous binding to both kinds of receptors would allow for effective inter-cellular signal transmission for the benefit of the patient (Bone, volume 19 (1996), page 569-574).

[0006] A disadvantage of the use of these proteins as medicaments and their production is, that they are not readily obtainable in biologically active and sufficiently pure form by recombinant expression in prokaryotes without intensive renaturation procedures.

[0007] Thus it was the object of the present invention to provide a simple and inexpensive possibility to reproducibly produce proteins exhibiting high biological activity, wherein this biological activity should essentially correspond to that of the dimers of the proteins of said families.

[0008] This object is solved according to the invention by a protein selected from the members of the TGF- $\beta$  protein superfamily, such protein being necessarily monomeric due to substitution or deletion of a cysteine which is responsible for dimeric formation.

[0009] Surprisingly it has been found that the substitution or deletion of the cysteine, which normally effects the dimerization in the proteins, results upon expression and correct folding (proper formation of the intramolecular disulfide bridges) in a monomeric protein that retains the biological activity of the dimeric form. Even more surprisingly, it was found that at least some of the monomeric proteins show a higher activity, based on the weight of protein, than their respective dimeric forms. Apart from this improved biological activity an important advantage for the proteins according to the invention is that they can be expressed in a large amount in prokaryotic hosts and upon simple refolding of the monomers they are obtained in high purity and very high yield without the need to separate dimerized from non-dimerized (monomeric) protein. The findings of the present invention are very surprising since, as already mentioned above, it was common understanding that only a dimer of the morphogenetic proteins has biological activity. Despite this understanding the proteins according to the invention show an up to two-fold higher activity than that of the dimer on the basis of protein weight. The smaller size of the proteins of the invention, while maintaining the biological activity, can also be considered as advantageous, e.g. for applications concerning the brain since the monomeric protein can much easier pass the blood-brain-barrier than the dimeric form.

[0010] The proteins according to the invention encompass all proteins of the mentioned protein families that are normally present in dimeric form. Also parts of such proteins that retain substantial activity or fusion proteins or precursor forms of proteins shall be considered as encompassed by the present invention as well as biologically active naturally occurring or biosynthetic variants of TGF- $\beta$  superfamily proteins, as long as they show at least considerable biological activity.


[0011] In a preferred embodiment of the present invention the monomeric protein is a mature protein or a biologically active part or variant thereof. The term "biologically active part or variant thereof" is meant to define either fragments retaining activity, precursor proteins that are e.g. cleaved at the site of activity to the mature form or show biological activity themselves, or also variants that still maintain essentially the biological activity of the wild-type protein. Such variants preferably contain conservative amino acid substitutions, but especially at the N-terminal part of the mature proteins even considerable deletions or substitutions do not lead to a considerable loss of biological activity. It is well within the skill of the man in the art to determine whether a certain protein shows the required biological activity. Proteins showing at least 70% and preferably at least 80% homology to the mature wild-type proteins of the above referenced protein families should be understood as encompassed by the present invention, as long as they contain the deletion or substitution of a cysteine, as required for the proteins according to the invention, and therefore do not form dimers.

[0012] It is especially preferred that proteins according to the invention contain at least the 7 cysteine region characteristic for the TGF- $\beta$  protein superfamily.

[0013] This specific 7 cysteine region is considered to be the most important part of the proteins in view of the biological activity. Therefore proteins retaining this critical region are preferred proteins according to the invention. It is disclosed in the state of the art which cysteine is responsible in a certain protein family or protein for dimer formation (see for example: Schluenzer & Grutter (1992) Nature 358, 430-434; Daopin et al., (1992) Science 257, 369-373 and Griffith et al., Proc. Natl. Acad. Sci. 93 (1996), page 878-883). This cysteine has to be deleted or substituted by another amino acid to form a protein according to the invention.

[0014] The 7 cysteine region is known for many proteins of the TGF- $\beta$  protein superfamily. In this region the respective location of the cysteine residues to each other is important and is only allowed to vary slightly in order not to lose the biological activity. Consensus sequences for such proteins are known in the state of the art and all proteins complying with such consensus sequences are considered to be encompassed by the present invention.

[0015] In an especially preferred embodiment of the present invention the protein contains a consensus sequence according to the following sequence



wherein C denotes cysteine, Y denotes any amino acid including cysteine and X denotes any amino acid except cysteine.

10                  [0016] More preferably the protein according to the invention contains a consensus sequence according to the following sequence



15                  wherein C, X and Y have the same meaning as defined above.

[0017] Even more preferably the protein according to the invention contains a consensus sequence according to the following sequence



wherein C and X have the same meaning as defined above.

[0018] In these consensus sequences especially preferred distances between the respective cysteine residues are contained, wherein also already the dimer forming cysteine is substituted by another amino acid. As with all proteins of said protein superfamily the location of and distance between the cysteines is more important than the identity of the other amino acids contained in this region. Therefore, the consensus sequence shows the respective location of the cysteines, but does not show the identity of the other amino acids, since these other amino acids are widely variable in the proteins of the TGF- $\beta$  protein superfamily.

25                  [0019] In a preferred embodiment of the present invention the monomeric protein according to the invention is a morphogenetic protein.

[0020] Most of the members of the TGF- $\beta$  protein superfamily are morphogenetic proteins that are useful for treatments where regulation of differentiation and proliferation of cells or progenitor cells is of interest. This can result in replacement of damaged and/or diseased tissue like for example skeletal (bone, cartilage) tissue, connective tissue, periodontal or dental tissue, neural tissue, tissue of the sensory system, liver, pancreas, cardiac, blood vessel and renal tissue, uterine or thyroid tissue etc. Morphogenetic proteins are often useful for the treatment of ulcerative or inflammatory tissue damage and wound healing of any kind such as enhanced healing of ulcers, burns, injuries or skin grafts. Especially preferred proteins according to the invention belong to the TGF- $\beta$ , BMP, GDF, activin or GDNF families. Several BMP proteins which were originally discovered by their ability to induce bone formation, have been described, as also indicated above. Meanwhile, several additional functions have been found as it is also true for members of the GDFs. These proteins show a very broad field of applications and especially are in addition to their bone and cartilage growth promoting activity (see for example: WO 88/00205, WO 90/11366, WO 91/05802) useful in periodontal disease, for inhibiting periodontal and tooth tissue loss, for sealing tooth cavities, for enhancing integration of a tooth in a tooth socket (see for example: WO 96/26737, WO 94/06399, WO 95/24210), for connective tissue such as tendon or ligament (see for example: WO 95/16035), for improving survival of neural cells, for inducing growth of neural cells and repairing neural defects, for damaged CNS tissue due to stroke or trauma (see for example: WO 97/34626, WO 94/03200, WO 95/05846), for maintaining or restoring sensory perception (see for example WO 98/20890, WO 98/20889), for renal failure (see for example: WO 97/41880, WO 97/41881), for liver regeneration (see for example WO 94/06449), for regeneration of myocardium (see for example WO 98/27995), for treatment or preservation of tissues or cells for organ or tissue transplantation, for integrity of gastrointestinal lining (see for example WO 94/06420), for increasing progenitor cell population as for example hematopoietic progenitor cells by *ex vivo* stimulation (see for example WO 92/15323), etc. One preferred member of the GDF family is the protein MP52 which is also termed GDF-5 or CDMP-1. Applications for MP52 reflect several of the already described applications for the BMP/GDF family. MP52 is considered to be a very effective promoter of bone and cartilage formation as well as connective tissue formation (see for example WO 95/04819, Höttgen et al., (1996), Growth Factors 13, 65-74, Storm et al., (1994) Nature 368, 639-643, Chang et al., (1994) J. Biol. Chem. 269 (45), 28227-28234). In this connection MP52 is useful for applications concerning the joints between skeletal elements (see for example Storm & Kingsley (1996) Development 122, 3969-3979). One example for connective tissue is tendon and ligament (Wolfman et al., (1997), J. Clin. Invest.

100, 321-330, Aspenberg & Forslund (1999), Acta Orthop Scand 70, 51-54, WO 95/16035). MP52 is also useful for tooth (dental and periodontal) applications (see for example WO 95/04819, WO 93/16099, Morotome et al. (1998), Biochem Biophys Res Comm 244, 85-90). MP52 is useful in wound repair of any kind. It is in addition very useful for promoting tissue growth in the neuronal system and survival of dopaminergic neurons, for example. MP52 in this connection is useful for applications in neurodegenerative diseases like e.g. Parkinson's disease and possibly also Alzheimer's disease for Huntington chorea tissues (see for example WO 97/03188, Kriegstein et al., (1995) J. Neurosci Res. 42, 724-732, Sullivan et al., (1997) Neurosci Lett 233, 73-76, Sullivan et al. (1998), Eur. J. Neurosci 10, 3681-3688). MP52 allows to maintain nervous function or to retain nervous function in already damaged tissues. MP52 is therefore considered to be a generally applicable neurotrophic factor. It is also useful for diseases of the eye, in particular retina cornea and optic nerve (see for example WO 97/03188, You et al. (1999), Invest Ophthalmol Vis Sci 40, 296-311). The monomeric MP52 is expected to show all the already described activities of the dimeric form as well as some further described activities as described for the dimeric BMP/GDF family members. It is expected to be for example also useful for increasing progenitor cell populations and for stimulating differentiation of progenitor cells *ex vivo*. Progenitor cells can be cells which take part in the cartilage formation process or hematopoietic progenitor cells. It is also useful for damaged or diseased tissue where a stimulation of angiogenesis is advantageous (see for example: Yamashita et al. (1997), Exp Cell Res 235, 218-226).

**[0021]** An especially preferred protein according to the invention therefore is protein MP52 or a biologically active part or variant thereof. Like in the already above mentioned definition of these terms MP52 can e.g. be used in its mature form, however, it can also be used as a fragment thereof at least containing the 7 cysteine region or also in a precursory form. Deviations at the N-terminal part of mature MP52 do not affect its activity to a considerable degree. Therefore, substitutions, deletions or additions on the N-terminal part of the proteins are still within the scope of the present invention. It might be useful to add a peptide to the N-terminal part of the protein, e.g. for purification reasons. It might not be necessary to cleave off this added peptide after expression and purification of the protein. Additional peptides at the N- or C-terminal part of the protein may also serve for the targeting of the protein to special tissues such as nerve or bone tissue or for the penetration of the blood/brain barrier. Generally, also fusion proteins of a monomeric protein according to the invention and another peptide or group are considered within the scope of the present invention, wherein these other peptides or groups are directing the localization of the fusion protein, e.g. because of an affinity to a certain tissue type etc. Examples for such fusion proteins are described in WO 97/23612. The protein containing such addition will retain its biological activity at least as long as such addition does not impair the formation of the biologically active conformation of the protein.

**[0022]** In an especially preferred embodiment of the present invention the proteins comprises the amino acid sequence according to SEQ.ID.NO.1 (DNA and protein sequence) and SEQ.ID.No.2 (protein sequence, only), respectively. SEQ.ID.NO.2 shows the complete protein sequence of the prepro protein of human MP52, as already disclosed in WO 95/04819. The start of the mature protein lies preferably in the area of amino acids 352-400, especially preferred at amino acids 381 or 382. Therefore, the mature protein comprises amino acids 381-501 or 382-501. The first alanine of the mature protein can be deleted and the mature protein then preferably comprises amino acids 383-501. The cysteine at position 465 that is present in the already described dimeric MP52 protein is according to the invention either deleted or substituted by another amino acid. This deletion or substitution is represented by Xaa at the respective position in SEQ.ID.Nos. 1 and 2.

**[0023]** The activin/inhibin family proteins are of interest for applications related to contraception, fertility and pregnancy (see for example WO 94/19455, U.S. 5,102,868). They are also of interest for applications like repair or prevention of diseases of the nervous system, they can be used in the repair of organ tissue such as liver and even in bone and cartilage, too. In this connection MP121 (activin  $\beta$ C) is especially useful in applications for growth or regeneration of damaged and/or diseased tissue, especially the liver tissue, neural tissue, skeletal tissue (see for example WO 96/01316, WO 98/22492 and WO 97/03188). MP121 is known to be predominantly expressed in the liver whereby the mRNA is markedly reduced after partial hepatectomy. MP121 is expected to regulate the liver mass (Zhang et al., Endocrine Journal 44 (1997), page 759-764). The monomeric MP121 shows all the already described activities of the dimeric form as well as some further described activities as described for the dimeric TGF- $\beta$  superfamily members. It is for example also expected to be useful in treatment of ulceration (for example stomach ulceration) and useful for integrity of gastrointestinal lining and for stimulating differentiation of progenitor cells *ex vivo*, treatment or preservation of mammalian tissue or cells, e.g. for organ or tissue transplantation.

**[0024]** A further preferred protein according to the invention therefore is MP121, a member of the activin/inhibin protein family. Also for this protein a biologically active part or variant thereof is encompassed by the present invention according to the above defined rules. An especially preferred embodiment is shown in SEQ.ID.NO.3 (DNA and protein sequence) and SEQ.ID.NO.4 (protein sequence, only) respectively. SEQ.ID.NO.4 shows the complete amino acid sequence of the prepro protein of human MP121, that has already been disclosed in WO 96/01316. The start of the mature protein lies preferably between amino acids 217 and 247, most preferred at amino acid 237. A preferred mature protein therefore comprises the mature part of the protein starting at amino acid 237 and ending at amino acid 352.

However, also the precursor protein comprising the whole shown amino acid sequence is encompassed by the present invention. The cysteine at position 316 is according to the invention either deleted or substituted by another amino acid, being represented by Xaa in SEQ.ID.Nos.3 and 4.

**[0025]** The amino acid by which the cysteine residue effecting the dimerization is substituted can be selected by any 5 amino acid that does not impair the formation of a biologically active conformation. The amino acid is preferably selected from the group of alanine, serine, threonine, leucine, isoleucine, glycine and valine.

**[0026]** The proteins according to the invention are in summary characterized by the absence of the cysteine residue 10 in the amino acid sequence responsible for the dimer formation. This absence can be effected by substitution of this cysteine by another amino acid or by deletion. In case of deletion, however, it must be assured for the protein that the formation of the biologically active conformation is not hindered. The same is true for the selection of the substitution amino acid, wherein it is preferred to use an amino acid which has a form similar to cysteine.

**[0027]** The monomeric proteins according to the invention can be easily produced, in particular by expression 15 in prokaryotes and renaturation according to known methods. It is advantageous that the protein can be obtained in exceedingly biologically active form. The proteins exhibit in monomeric form about the same activity as the dimer so that based on the amount of active substance only half of the monomeric protein has to be used in order to obtain the same positive biological effects.

**[0028]** A further subject matter of the present invention is a nucleic acid encoding a protein according to the invention. 20 It is obvious that the nucleic acid has to have such a sequence that a deletion or substitution of the cysteine responsible for the dimer formation is achieved. The nucleic acid can be a naturally occurring nucleic acid, but also a recombinantly produced or processed nucleic acid. The nucleic acid can be both a DNA sequence and an RNA sequence, as long as the protein according to the invention can be obtained from this nucleic acid upon expression in a suitable system.

**[0029]** In a preferred embodiment of the invention the nucleic acid is a DNA sequence. This DNA sequence in an especially preferred embodiment of the invention comprises a sequence as shown in SEQ.ID.NO.1 and SEQ.ID.NO. 25 3, respectively, or parts thereof. SEQ.ID.NO.1 shows a nucleic acid encoding MP52, wherein the codon for the cysteine responsible for the dimer formation is replaced by another codon which does not encode cysteine or deleted. This substitution or deletion is shown as "nnn" in the sequence protocols. SEQ.ID.NO.3 shows a nucleic acid encoding MP121, wherein also the codon for the cysteine effecting the dimer formation is replaced by a respective different codon or deleted. Instead of the complete sequences of SEQ.ID.NOs.1 or 3 also parts can be used that encode the mature proteins or fragments also described above.

**[0030]** It is preferred in the framework of the present invention that the nucleic acid apart from the coding sequences 30 also contains expression control sequences. Such expression control sequences are known to the man skilled in the art and serve to control the expression of the encoded protein in a host cell. The host cell does not have to be an isolated cell, moreover, the nucleic acid can be expressed in the patient *in vivo* in the target tissue. This can be done by inserting the nucleic acid into the cell genome, however, it is also possible to transform host cells with expression 35 vectors containing a nucleic acid according to the invention. Such expression vectors are a further subject matter of the present invention, wherein the nucleic acid is inserted in a suitable vector system, the vector system being selected according to the desired expression of the protein. The vector system can be a eukaryotic vector system, but - in the framework of the present invention - it is preferably a prokaryotic vector system, with which the proteins can be produced in prokaryotic host cells in a particularly easy and pure manner. In addition, the expression vector can be a viral vector.

**[0031]** Also host cells in turn are a further subject matter of the present invention. The host cells are characterized 40 in that they contain a nucleic acid according to the invention or an expression vector according to the invention and that they are able to use the information present in the nucleic acids and in the expression vector, respectively, for the expression of a monomeric protein according to the invention.

**[0032]** Although in the framework of the present invention also eukaryotic host cells are suitable for the production 45 of the protein, it is, as mentioned already several times above, particularly advantageous that the protein according to the invention can be produced in prokaryotic host cells, which therefore represent a preferred embodiment of the present invention.

**[0033]** After such preferred expression in prokaryotic host cells the protein is purified and renatured according to known methods, thereby effecting intramolecular cystine bridge formation.

**[0034]** Since, however, not only *in vitro* production of the monomeric protein is possible, but also *in vivo* expression 50 of a nucleic acid according to the invention, a further preferred embodiment is a eukaryotic host cell, and especially a eukaryotic host cell containing the DNA in its genome, or as an expression vector. Such host cell can also be useful for application to an individual in need of morphogenic treatment.

**[0035]** Further subject matters of the present application are pharmaceutical compositions comprising at least one 55 monomeric protein according to the invention or at least one nucleic acid encoding for such a protein or at least one corresponding expression vector, or at least one eukaryotic host cell expressing the monomeric protein.

**[0036]** The protein itself, but also a nucleic acid according to the invention, an expression vector or a host cell can be considered to be advantageous as active substances in a pharmaceutical composition. Also combinations of mon-

omeric proteins, with either biological activities in the same or different applications, can be used in preferred pharmaceutical compositions. Especially preferred for neuronal applications are combinations of MP52 with other TGF- $\beta$  superfamily proteins, both in monomeric form, like for example with GDNF (see WO 97/03188). Also preferred for neuronal applications are combinations of TGF- $\beta$  with GDNF, both in monomeric form. Also for applications concerning cartilage and/or bone the combination of several monomeric proteins might be useful, like MP52 with a protein of TGF- $\beta$  (see e.g. WO 92/09697) or MP52 with a cartilage maintenance-inducing protein such as BMP-9 (see e.g. WO 96/39170). When a nucleic acid or an expression vector is used, however, it has to be ensured that when administering to the patient there has to be an environment in which the nucleic acid and the expression vector, respectively, can be expressed and the protein according to the invention can be produced in vivo at the site of action. The same applies accordingly to the host cell according to the invention. When using expression vectors or host cells it is also possible that they encode more than one monomeric protein of the invention to produce a combination of two or more monomeric proteins.

**[0037]** It is advantageous to both the protein and the nucleic acid or the expression vector or the host cell when they are applied in and/or on a biocompatible matrix. The matrix material can be transplanted into the patient, e.g. surgically, wherein the protein either is effective on the surface of the matrix material or the protein or the DNA encoding the protein can be slowly released from the matrix material and then be effective over a long period of time. Additionally it is possible and advantageous to use a biodegradable matrix material in the pharmaceutical composition, wherein this material preferably dissolves during the protein induced tissue formation so that a protein or a nucleic acid contained therein is released and the newly formed tissue replaces the matrix material.

**[0038]** Finally, in case of applications relating to bone formation, it is advantageous to use a matrix material which is itself e.g. osteogenically active. By using such a matrix material it becomes possible to achieve a synergistic effect of protein and matrix material and to effect a particularly rapid and effective bone formation.

**[0039]** An especially preferred matrix material that can be used according to the invention is a matrix material as described in U.S. 5,231,169 and U.S. 5,776,193 and especially for applications like spinal fusion.

**[0040]** When using a combination of a matrix material and protein and/or nucleic acid and/or expression vector, it is preferable to sterilize such a combination prior to its use. The matrix and the morphogenetic protein can be separately sterilized and then combined, but it is preferred to terminally sterilize the device consisting of matrix and morphogenetic protein. Terminal sterilization can be achieved by ionizing radiation as already described for dimeric proteins (U.S. 5,674,292) but it is also advantageous to use ethylene oxide.

**[0041]** Of course this invention also comprises pharmaceutical compositions containing further substances like e.g. pharmacologically acceptable auxiliary and carrier substances. However, the protein according to the invention, also in case a matrix material is used, does not necessarily have to be used together with this matrix material, but can also be administered systemically, wherein it concentrates preferably in the surrounding of an implanted matrix material.

**[0042]** For some applications the protein according to the invention and the nucleic acid forming this protein, respectively or the expression vector or host cell can preferably be present in an injectable composition. Implants are not necessary or possible for every form of application of the proteins according to the invention. However, it is also possible to provide an implantable vessel or an implantable micropump containing for example semipermeable membranes in which the protein according to the invention or the nucleic acid generating it is contained, from which either one is slowly released over a prolonged period of time. The pharmaceutical composition according to the invention can also contain other vehicles which make it possible that the proteins or the nucleic acids or the expression vectors encoding these proteins be transported to the site of activity and released there, wherein e.g. liposomes or nanospheres can be used. In principle, it is also possible to apply host cells, like e.g. implanted embryonic cells expressing the proteins. Cells transfected with recombinant DNA may be encapsulated prior to implantation. Any other practicable but herein not explicitly described form of application of the pharmaceutical composition according to the invention and their corresponding manufacture are also comprised by the present invention, as long as they contain a protein according to the invention or a nucleic acid or an expression vector coding therefor, or a host cell expressing it.

**[0043]** Although the indications shall not be restricted herein and all indications exhibiting the dimeric form of the protein according to the invention are also comprised, in the following types of application for the compositions according to the invention are listed which are considered to be particularly preferred indications for the proteins of the present invention. On the one hand, there is the prevention or therapy of diseases associated with bone and/or cartilage damage or affecting bone and/or cartilage disease, or generally situations, in which cartilage and/or bone formation is desirable or for spinal fusion, and on the other hand, there is prevention or therapy of damaged or diseased tissue associated with connective tissue including tendon and/or ligament, periodontal or dental tissue including dental implants, neural tissue including CNS tissue and neuropathological situations, tissue of the sensory system, liver, pancreas, cardiac, blood vessel, renal, uterine and thyroid tissue, skin, mucous membranes, endothelium, epithelium, for promotion or induction of nerve growth, tissue regeneration, angiogenesis, wound healing including ulcers, burns, injuries or skin grafts, induction of proliferation of progenitor cells or bone marrow cells, for maintenance of a state of proliferation or differentiation for treatment or preservation of tissue or cells for organ or tissue transplantation, for integrity of gastroin-

intestinal lining, for treatment of disturbances in fertility, contraception or pregnancy.

[0044] Diseases concerning sensory organs like the eye are also to be included in the preferred indication of the pharmaceutical composition according to the invention. As neuronal diseases again Parkinson's and Alzheimer's diseases can be mentioned as examples.

5 [0045] The pharmaceutical compositions according to the invention can be used in any desired way, the pharmaceutical compositions are formulated preferably for surgical local application, topical or systemic application. Auxiliary substances for the individual application form can of course be present in the pharmaceutical composition according to the invention. For some applications it can be advantageous to add some further substances to the pharmaceutical composition as for example Vitamin D (WO 92/21365), parathyroid hormone related peptide (WO 97/35607), chordin (WO 98/21335), anti-fibrinolytic agent (EP 535091), anti-metabolites (WO 95/09004), alkyl cellulose (WO 93/00050), mannitol (WO 98/33514), sugar, glycine, glutamic acid hydrochloride (U.S. 5,385,887), antibiotics, antiseptics, amino acids and/or additives which improve the solubility or stability of the monomeric morphogenetic protein as for example nonionic detergents (e.g. Tween 80), basic amino acids, carrier proteins (e.g. serum albumin), full length propeptides of the TGF- $\beta$  superfamily or parts thereof.

10 [0046] As can be already gathered from the description of proteins, nucleic acids and pharmaceutical compositions, the proteins according to the invention and respective nucleic acids, which provide for an expression of the proteins at the site of activity, can advantageously be applied in all areas for which also the dimeric forms of the proteins, as described, can be applied. In the framework of the present invention therefore a further subject matter is the use of a pharmaceutical composition according to the present invention for the treatment or prevention of any indications of the 15 dimeric forms of the proteins according to the invention.

[0047] Herein it is again possible to conduct surgical operations and to implant the pharmaceutical composition (in particular contained on a matrix material), an administration in liquid or otherwise suitable form via, e.g. injection or oral administration seems to be as suitable as a topical application for e.g. tissue regeneration.

20 [0048] Fig. 1A shows a two dimensional graph of the conformation of recombinantly produced dimeric MP52 with the deleted first alanine. In this figure the 7 cysteine bridges contained in a dimer are shown, wherein there are 3 intramolecular cystine bridges per monomer unit and 1 intermolecular cystine bridge connecting both monomers. Fig. 25 1B shows the monomeric protein according to the invention wherein the cysteine of the amino acid sequence of MP52 has been replaced by X that denotes any amino acid except cysteine.

30

35

40

45

50

55

## SEQUENCE LISTING

5           <110> HyGene AG  
10          <120> Monomeric Protein of the TGF-beta Family  
15          <130> 20780PEP Monomeric TGF-beta protein  
20          <140>  
25          <141>  
30          <160> 4  
35          <170> PatentIn Ver. 2.1  
40          <210> 1  
45          <211> 2703  
50          <212> DNA  
55          <213> Homo sapiens  
60          <220>  
65          <221> CDS  
70          <222> (640)..(2142)  
75          <400> 1  
80          ccatggcctc gaaagggcag cggtgatttt tttcacataa atatatcgca cttaaatgag 60  
85          tttagacagc atgacatcag agagtaatta aattggtttg gggttggatt ccgtttccaa 120  
90          ttcctgagtt caggtttgta aaagattttt ctgagcacct gcaggcctgt gagtgtgtgt 180  
95          gtgtgtgtgt gtgtgtgtgt gtgtgtgtga agtattttca ctggaaagga ttcaaaaacta 240  
100         gggggaaaaaa aaaactggag cacacaggca gcattacgcc attcttcctt cttggaaaaaa 300  
105         tccctcagcc ttatacaagc ctccttcaag ccctcagtca gttgtgcagg agaaaggggg 360

EP 1 074 620 A1

cggttggctt tctcctttca agaacgagtt atttcagct gctgactgga gacggtgac 420

5 gtctggatac gagagcattt ccactatggg actggataaca aacacacacc cgccagactt 480

10 caagagtctc agactgagga gaaaggcttt cttctgctg ctactgctgc tgccgctgct 540

tttcaaagtc cactccttcc atggtttttc ctgccaaacc agaggcacct ttgctgctgc 600

15 cgctgttctc tttgggtgtca ttcagcggct ggccagagg atg aga ctc ccc aaa 654

Met Arg Leu Pro Lys  
20 1 5

ctc ctc act ttc ttg ctt tgg tac ctg gct tgg ctg gac ctg gaa ttc 702

25 Leu Leu Thr Phe Leu Leu Trp Tyr Leu Ala Trp Leu Asp Leu Glu Phe  
10 15 20

30 atc tgc act gtg ttg ggt gcc cct gac ttg ggc cag aga ccc cag ggg 750  
Ile Cys Thr Val Leu Gly Ala Pro Asp Leu Gly Gln Arg Pro Gln Gly  
25 30 35

35 acc agg cca gga ttg gcc aaa gca gag gcc aag gag agg ccc ccc ctg 798  
Thr Arg Pro Gly Leu Ala Lys Ala Glu Ala Lys Glu Arg Pro Pro Leu  
40 45 50

45 40 45 50  
40 gcc cgg aac gtc ttc agg cca ggg ggt cac agc tat ggt ggg ggg gcc 846

50 Ala Arg Asn Val Phe Arg Pro Gly Gly His Ser Tyr Gly Gly Ala  
55 60 65

acc aat gcc aat gcc agg gca aag gga ggc acc ggg cag aca gga ggc 894

55 Thr Asn Ala Asn Ala Arg Ala Lys Gly Gly Thr Gly Gln Thr Gly Gly  
70 75 80 85

ctg aca cag ccc aag aag gat gaa ccc aaa aag ctg ccc ccc aga ccg 942  
55 Leu Thr Gln Pro Lys Lys Asp Glu Pro Lys Lys Leu Pro Pro Arg Pro

## EP 1 074 620 A1

	90	95	100														
5	ggc ggc cct gaa ccc aag cca gga cac cct ccc caa aca agg cag gct 990																
	Gly	Gly	Pro	Glu	Pro	Lys	Pro	Gly	His	Pro	Pro	Gln	Thr	Arg	Gln	Ala	
		105					110							115			
10	aca gcc cgg act gtg acc cca aaa gga cag ctt ccc gga ggc aag gca 1038																
	Thr	Ala	Arg	Thr	Val	Thr	Pro	Lys	Gly	Gln	Leu	Pro	Gly	Gly	Lys	Ala	
15		120					125							130			
	ccc	cca	aaa	gca	gga	tct	gtc	ccc	agc	tcc	ttc	ctg	ctg	aag	aag	gcc	1086
20	Pro	Pro	Lys	Ala	Gly	Ser	Val	Pro	Ser	Ser	Phe	Leu	Leu	Lys	Lys	Ala	
		135					140							145			
	agg	gag	ccc	ggg	ccc	cca	cga	gag	ccc	aag	gag	ccg	ttt	cgc	cca	ccc	1134
25	Arg	Glu	Pro	Gly	Pro	Pro	Arg	Glu	Pro	Lys	Glu	Pro	Phe	Arg	Pro	Pro	
		150					155					160			165		
	ccc	atc	aca	ccc	cac	gag	tac	atg	ctc	tcg	ctg	tac	agg	acg	ctg	tcc	1182
30	Pro	Ile	Thr	Pro	His	Glu	Tyr	Met	Leu	Ser	Leu	Tyr	Arg	Thr	Leu	Ser	
		170					175					180					
35	gat	gct	gac	aga	aag	gga	ggc	aac	agc	agc	gtg	aag	ttg	gag	gct	ggc	1230
	Asp	Ala	Asp	Arg	Lys	Gly	Gly	Asn	Ser	Ser	Val	Lys	Leu	Glu	Ala	Gly	
40		185					190					195					
	ctg	gcc	aac	acc	atc	acc	agc	ttt	att	gac	aaa	ggg	caa	gat	gac	cga	1278
	Leu	Ala	Asn	Thr	Ile	Thr	Ser	Phe	Ile	Asp	Lys	Gly	Gln	Asp	Asp	Arg	
45													205		210		
	ggt	ccc	gtg	gtc	agg	aag	cag	agg	tac	gtg	ttt	gac	att	agt	gcc	ctg	1326
50	Gly	Pro	Val	Val	Arg	Lys	Gln	Arg	Tyr	Val	Phe	Asp	Ile	Ser	Ala	Leu	
		215					220					225					
	gag	aag	gat	ggg	ctg	ctg	ggg	gcc	gag	ctg	cgg	atc	ttg	cgg	aag	aag	1374
55	Glu	Lys	Asp	Gly	Leu	Leu	Gly	Ala	Glu	Leu	Arg	Ile	Leu	Arg	Lys	Lys	

## EP 1 074 620 A1

230	235	240	245	
ccc tcg gac acg gcc aag cca gcg gcc ccc gga ggc ggg cg <sup>g</sup> gct gcc 1422				
5 Pro Ser Asp Thr Ala Lys Pro Ala Ala Pro Gly Gly Arg Ala Ala				
250 255 260				
10 cag ctg aag ctg tcc agc tgc ccc agc ggc cg <sup>g</sup> cag cc <sup>g</sup> gcc tcc ttg 1470				
Gln Leu Lys Leu Ser Ser Cys Pro Ser Gly Arg Gln Pro Ala Ser Leu				
265 270 275				
15 ctg gat gtg cgc tcc gtg cca ggc ctg gac gga tct ggc tgg gag gtg 1518				
Leu Asp Val Arg Ser Val Pro Gly Leu Asp Gly Ser Gly Trp Glu Val				
20 280 285 290				
ttc gac atc tgg aag ctc ttc cga aac ttt aag aac tcg gcc cag ctg 1566				
25 Phe Asp Ile Trp Lys Leu Phe Arg Asn Phe Lys Asn Ser Ala Gln Leu				
295 300 305				
30 tgc ctg gag ctg gag gcc tgg gaa cg <sup>g</sup> ggc agg gcc gtg gac ctc cgt 1614				
Cys Leu Glu Leu Glu Ala Trp Glu Arg Gly Arg Ala Val Asp Leu Arg				
310 315 320 325				
35 ggc ctg ggc ttc gac cgc gcc cg <sup>g</sup> cag gtc cac gag aag gcc ctg 1662				
Gly Leu Gly Phe Asp Arg Ala Ala Arg Gln Val His Glu Lys Ala Leu				
330 335 340				
40 ttc ctg gtg ttt ggc cgc acc aag aaa cg <sup>g</sup> gac ctg ttc ttt aat gag 1710				
Phe Leu Val Phe Gly Arg Thr Lys Lys Arg Asp Leu Phe Phe Asn Glu				
45 345 350 355				
att aag gcc cgc tct ggc cag gac gat aag acc gtg tat gag tac ctg 1758				
50 Ile Lys Ala Arg Ser Gly Gln Asp Asp Lys Thr Val Tyr Glu Tyr Leu				
360 365 370				
55 ttc agc cag cg <sup>g</sup> cga aaa cg <sup>g</sup> cg <sup>g</sup> gcc cca ctg gcc act cgc cag ggc 1806				
Phe Ser Gln Arg Arg Lys Arg Arg Ala Pro Leu Ala Thr Arg Gln Gly				

## EP 1 074 620 A1

375

380

385

aag cga ccc agc aag aac ctt aag gct cgc tgc agt cg<sup>g</sup> aag gca ctg 1854

5

Lys Arg Pro Ser Lys Asn Leu Lys Ala Arg Cys Ser Arg Lys Ala Leu  
390 395 400 405

10

cat gtc aac ttc aag gac atg ggc tgg gac gag tgg atc atc gca ccc 1902

His Val Asn Phe Lys Asp Met Gly Trp Asp Asp Trp Ile Ile Ala Pro  
410 415 420

15

ctt gag tac gag gct ttc cac tgc gag ggg ctg tgc gag ttc cca ttg 1950

20

Leu Glu Tyr Glu Ala Phe His Cys Glu Gly Leu Cys Glu Phe Pro Leu  
425 430 435cg<sup>c</sup> tcc cac ctg gag ccc acg aat cat gca gtc atc cag acc ctg atg 1998

25

Arg Ser His Leu Glu Pro Thr Asn His Ala Val Ile Gln Thr Leu Met  
440 445 450

30

aac tcc atg gac ccc gag tcc aca cca ccc acc nnn tgt gtg ccc acg 2046

Asn Ser Met Asp Pro Glu Ser Thr Pro Pro Thr Xaa Cys Val Pro Thr  
455 460 465

35

cg<sup>g</sup> ctg agt ccc atc agc atc ctc ttc att gac tct gcc aac aac gtg 2094Arg Leu Ser Pro Ile Ser Ile Leu Phe Ile Asp Ser Ala Asn Asn Val  
470 475 480 485

40

gtg tat aag cag tat gag gac atg gtc gtg gag tcg tgt ggc tgc agg 2142

Val Tyr Lys Gln Tyr Glu Asp Met Val Val Glu Ser Cys Gly Cys Arg  
490 495 500

45

tagcagca<sup>t</sup> ggccctctgt ct<sup>t</sup>ccctgggt ggcacatccc aagagccccct tcctgcactc 2202

50

ctggaatcac agaggggtca ggaagctgtg gcaggagcat ctacacagct tgggtgaaag 2262

55

gggattccaa taagcttgct cgctctctga gtgtgacttg ggctaaaggc ccccttttat 2322

**EP 1 074 620 A1**

ccacaagttc ccctggctga ggattgctgc ccgtctgctg atgtgaccag tggcaggcac 2382  
5 aggtccaggg agacagactc tgaatggac tgagtcccag gaaacagtgc ttccgatga 2442  
10 gactcagccc accatttctc ctcacctggg ccttctcaga ctctggactc tcctaagcac 2502  
15 ctctcaggag agccacaggt gccactgcct cctcaaataca catttgtgcc tggtgacttc 2562  
20 tggatagagt tgaggagtgt gaggctgtta gactgttaga tttaaatgtt tattgttag 2682  
25 ataaaaagca aaactgtgcc t 2703  
30 <210> 2  
<211> 501  
<212> PRT  
<213> Homo sapiens  
35 <400> 2  
Met Arg Leu Pro Lys Leu Leu Thr Phe Leu Leu Trp Tyr Leu Ala Trp  
1 5 10 15  
40 Leu Asp Leu Glu Phe Ile Cys Thr Val Leu Gly Ala Pro Asp Leu Gly  
20 25 30  
Gln Arg Pro Gln Gly Thr Arg Pro Gly Leu Ala Lys Ala Glu Ala Lys  
45 35 40 45  
Glu Arg Pro Pro Leu Ala Arg Asn Val Phe Arg Pro Gly Gly His Ser  
50 55 60  
50 Tyr Gly Gly Ala Thr Asn Ala Asn Ala Arg Ala Lys Gly Gly Thr  
65 70 75 80  
55 Gly Gln Thr Gly Gly Leu Thr Gln Pro Lys Lys Asp Glu Pro Lys Lys  
85 90 95

## EP 1074 620 A1

Leu Pro Pro Arg Pro Gly Gly Pro Glu Pro Lys Pro Gly His Pro Pro  
 100 105 110  
 5 Gln Thr Arg Gln Ala Thr Ala Arg Thr Val Thr Pro Lys Gly Gln Leu  
 115 120 125  
 10 Pro Gly Gly Lys Ala Pro Pro Lys Ala Gly Ser Val Pro Ser Ser Phe  
 130 135 140  
 15 Leu Leu Lys Lys Ala Arg Glu Pro Gly Pro Pro Arg Glu Pro Lys Glu  
 145 150 155 160  
 Pro Phe Arg Pro Pro Ile Thr Pro His Glu Tyr Met Leu Ser Leu  
 165 170 175  
 20 Tyr Arg Thr Leu Ser Asp Ala Asp Arg Lys Gly Gly Asn Ser Ser Val  
 180 185 190  
 25 Lys Leu Glu Ala Gly Leu Ala Asn Thr Ile Thr Ser Phe Ile Asp Lys  
 195 200 205  
 Gly Gln Asp Asp Arg Gly Pro Val Val Arg Lys Gln Arg Tyr Val Phe  
 210 215 220  
 30 Asp Ile Ser Ala Leu Glu Lys Asp Gly Leu Leu Gly Ala Glu Leu Arg  
 225 230 235 240  
 35 Ile Leu Arg Lys Lys Pro Ser Asp Thr Ala Lys Pro Ala Ala Pro Gly  
 245 250 255  
 40 Gly Gly Arg Ala Ala Gln Leu Lys Leu Ser Ser Cys Pro Ser Gly Arg  
 260 265 270  
 Gln Pro Ala Ser Leu Leu Asp Val Arg Ser Val Pro Gly Leu Asp Gly  
 275 280 285  
 45 Ser Gly Trp Glu Val Phe Asp Ile Trp Lys Leu Phe Arg Asn Phe Lys  
 290 295 300  
 50 Asn Ser Ala Gln Leu Cys Leu Glu Leu Glu Ala Trp Glu Arg Gly Arg  
 305 310 315 320  
 Ala Val Asp Leu Arg Gly Leu Gly Phe Asp Arg Ala Ala Arg Gln Val  
 325 330 335

**EP 1 074 620 A1**

His Glu Lys Ala Leu Phe Leu Val Phe Gly Arg Thr Lys Lys Arg Asp  
340 345 350

5 Leu Phe Phe Asn Glu Ile Lys Ala Arg Ser Gly Gln Asp Asp Lys Thr  
355 360 365

10 Val Tyr Glu Tyr Leu Phe Ser Gln Arg Arg Lys Arg Arg Ala Pro Leu  
370 375 380

15 Ala Thr Arg Gln Gly Lys Arg Pro Ser Lys Asn Leu Lys Ala Arg Cys  
385 390 395 400

Ser Arg Lys Ala Leu His Val Asn Phe Lys Asp Met Gly Trp Asp Asp  
405 410 415

20 Trp Ile Ile Ala Pro Leu Glu Tyr Glu Ala Phe His Cys Glu Gly Leu  
420 425 430

25 Cys Glu Phe Pro Leu Arg Ser His Leu Glu Pro Thr Asn His Ala Val  
435 440 445

Ile Gln Thr Leu Met Asn Ser Met Asp Pro Glu Ser Thr Pro Pro Thr  
450 455 460

30 Xaa Cys Val Pro Thr Arg Leu Ser Pro Ile Ser Ile Leu Phe Ile Asp  
465 470 475 480

35 Ser Ala Asn Asn Val Val Tyr Lys Gln Tyr Glu Asp Met Val Val Glu  
485 490 495

40 Ser Cys Gly Cys Arg  
500

45 <210> 3  
<211> 2272  
<212> DNA  
<213> Homo sapiens

50 <220>  
<221> CDS  
<222> (128)..(1183)

55 <400> 3

EP 1 074 620 A1

caaggagcca tgccagctgg acacacactt cttccagggc ctctggcagc caggacagag 60  
5 ttgagaccac agctgttgag accctgagcc ctgagtctgt attgctcaag aagggccttc 120  
cccagca atg acc tcc tca ttg ctt ctg gcc ttt ctc ctc ctg gct cca 169  
10 Met Thr Ser Ser Leu Leu Leu Ala Phe Leu Leu Leu Ala Pro  
1 5 10  
15 acc aca gtg gcc act ccc aga gct ggc ggt cag tgt cca gca tgt ggg 217  
Thr Thr Val Ala Thr Pro Arg Ala Gly Gly Gln Cys Pro Ala Cys Gly  
15 20 25 30  
20 ggg ccc acc ttg gaa ctg gag agc cag cg<sup>g</sup> gag ctg ctt ctt gat ctg 265  
Gly Pro Thr Leu Glu Leu Glu Ser Gln Arg Glu Leu Leu Leu Asp Leu  
25 35 40 45  
gcc aag aga agc atc ttg gac aag ctg cac ctc acc cag cgc cca aca 313  
30 Ala Lys Arg Ser Ile Leu Asp Lys Leu His Leu Thr Gln Arg Pro Thr  
50 55 60  
35 ctg aac cgc cct gtg tcc aga gct gct ttg agg act gca ctg cag cac 361  
Leu Asn Arg Pro Val Ser Arg Ala Ala Leu Arg Thr Ala Leu Gln His  
65 70 75  
40 ctc cac ggg gtc cca cag ggg gca ctt cta gag gac aac agg gaa cag 409  
Leu His Gly Val Pro Gln Gly Ala Leu Leu Glu Asp Asn Arg Glu Gln  
80 85 90  
45 gaa tgt gaa atc atc agc ttt gct gag aca ggc ctc tcc acc atc aac 457  
Glu Cys Glu Ile Ile Ser Phe Ala Glu Thr Gly Leu Ser Thr Ile Asn  
95 100 105 110  
50 cag act cgt ctt gat ttt cac ttc tcc tct gat aga act gct ggt gac 505  
Gln Thr Arg Leu Asp Phe His Phe Ser Ser Asp Arg Thr Ala Gly Asp  
55 115 120 125

## EP 1074 620 A1

agg gag gtc cag cag gcc agt ctc atg ttc ttt gtg cag ctc cct tcc 553  
 5 Arg Glu Val Gln Gln Ala Ser Leu Met Phe Phe Val Gln Leu Pro Ser  
                  130                       135                       140  
  
 aat acc act tgg acc ttg aaa gtg aga gtc ctt gtg ctg ggt cca cat 601  
 10 Asn Thr Thr Trp Thr Leu Lys Val Arg Val Leu Val Leu Gly Pro His  
       145                       150                       155  
  
 aat acc aac ctc acc ttg gct act cag tac ctg ctg gag gtg gat gcc 649  
 15 Asn Thr Asn Leu Thr Leu Ala Thr Gln Tyr Leu Leu Glu Val Asp Ala  
       160                       165                       170  
  
 20 agt ggc tgg cat caa ctc ccc cta ggg cct gaa gct caa gct gcc tgc 697  
  
 Ser Gly Trp His Gln Leu Pro Leu Gly Pro Glu Ala Gln Ala Ala Cys  
 175                       180                       185                       190  
 25 agc cag ggg cac ctg acc ctg gag ctg gta ctt gaa ggc cag gta gcc 745  
  
 Ser Gln Gly His Leu Thr Leu Glu Leu Val Leu Glu Gly Gln Val Ala  
 30                       195                       200                       205  
  
 cag agc tca gtc atc ctg ggt gga gct gcc cat agg cct ttt gtg gca 793  
  
 35 Gln Ser Ser Val Ile Leu Gly Gly Ala Ala His Arg Pro Phe Val Ala  
       210                       215                       220  
  
 40 gcc cgg gtg aga gtt ggg ggc aaa cac cag att cac cga cga ggc atc 841  
   Ala Arg Val Arg Val Gly Gly Lys His Gln Ile His Arg Arg Gly Ile  
       225                       230                       235  
  
 45 gac tgc caa gga ggg tcc agg atg tgc tgt cga caa gag ttt ttt gtg 889  
  
 Asp Cys Gln Gly Gly Ser Arg Met Cys Cys Arg Gln Glu Phe Phe Val  
 240                       245                       250  
  
 50 gac ttc cgt gag att ggc tgg cac gac tgg atc atc cag cct gag ggc 937  
  
 Asp Phe Arg Glu Ile Gly Trp His Asp Trp Ile Ile Gln Pro Glu Gly  
 255                       260                       265                       270

**EP 1 074 620 A1**

tac gcc atg aac ttc tgc ata ggg cag tgc cca cta cac ata gca ggc 985  
5 Tyr Ala Met Asn Phe Cys Ile Gly Gln Cys Pro Leu His Ile Ala Gly  
275 280 285  
  
atg cct ggt att gct gcc tcc ttt cac act gca gtg ctc aat ctt ctc 1033  
10 Met Pro Gly Ile Ala Ala Ser Phe His Thr Ala Val Leu Asn Leu Leu  
290 295 300  
  
aag gcc aac aca gct gca ggc acc act gga ggg ggc tca nnn tgt gta 1081  
15 Lys Ala Asn Thr Ala Ala Gly Thr Thr Gly Gly Ser Xaa Cys Val  
305 310 315  
  
ccc acg gcc cgg cgc ccc ctg tct ctg ctc tat tat gac agg gac agc 1129  
20 Pro Thr Ala Arg Arg Pro Leu Ser Leu Leu Tyr Tyr Asp Arg Asp Ser  
320 325 330  
25 aac att gtc aag act gac ata cct gac atg gta gta gag gcc tgt ggg 1177  
  
Asn Ile Val Lys Thr Asp Ile Pro Asp Met Val Val Glu Ala Cys Gly  
30 335 340 345 350  
  
tgc agt tagtctatgt gtggtatggg cagccccagg ttgcattggg aaacacgccc 1233  
35 Cys Ser  
  
ctacagaagt gcacttcctt gagaggaggg aatgacaccta ttctctgtcc agaatgtgga 1293  
  
40 ctcccttcttc ctgagcatct tatggaaatt accccacctt tgacttgaag aaaccttcat 1353  
  
45 ctaaagcaag tcactgtgcc atcttcctga ccactaccct ctttccttagg gcatagtcca 1413  
  
50 tccccctgtt ccatccccgtt agccccactc cagggactca gacccatctc caaccatgag 1473  
  
caatgccatc tggttcccgag gcaaagacac ccttagctca cctttaatag accccataac 1533  
  
55

**EP 1 074 620 A1**

ccactatgcc ttctgtcct ttctactcaa tggccccac tccaagatga gttgacacaa 1593  
5 ccccttcccc caattttgt ggatctccag agaggccctt ctggattc accaaagttt 1653  
10 agatcactgc tgccaaaaat agaggcttac ctaccccccctt cttgttg agccctgtc 1713  
15 cttcttagtt gtccaggtga actactaaag ctctcttgc atacccat ccatttttg 1773  
20 tccttctctg ctttctcta tgcccttaag gggtgacttg cctgagctct atcacctgag 1833  
25 gtctaggtgt catggttctg tgtaactgtg gctattctgt gtccctacac tacctggcta 1953  
30 cccccttcca tggccccagc tctgcctaca ttctgatttt tttttttttt ttttttttga 2013  
35 atacctgatg taatgaaaag aaaaagaaaa agacaaagct acaacagata aaagaccta 2133  
40 ggaatgtaca tctaattgac actacattgc attaatcaat agctgcactt tttgcaaact 2193  
45 gtggctatga cagtcctgaa caagaagggt ttctgttta agctgcagta actttctga 2253  
50 ctatggatca tcgttcctt 2272  
55 <210> 4  
<211> 352  
<212> PRT  
<213> Homo sapiens

## EP 1 074 620 A1

&lt;400&gt; 4

Met Thr Ser Ser Leu Leu Leu Ala Phe Leu Leu Leu Ala Pro Thr Thr  
 1 5 10 15

5

Val Ala Thr Pro Arg Ala Gly Gly Gln Cys Pro Ala Cys Gly Gly Pro  
 20 25 30

10

Thr Leu Glu Leu Glu Ser Gln Arg Glu Leu Leu Leu Asp Leu Ala Lys  
 35 40 45

15

Arg Ser Ile Leu Asp Lys Leu His Leu Thr Gln Arg Pro Thr Leu Asn  
 50 55 60

20

Arg Pro Val Ser Arg Ala Ala Leu Arg Thr Ala Leu Gln His Leu His  
 65 70 75 80

20

Gly Val Pro Gln Gly Ala Leu Leu Glu Asp Asn Arg Glu Gln Glu Cys  
 85 90 95

25

Glu Ile Ile Ser Phe Ala Glu Thr Gly Leu Ser Thr Ile Asn Gln Thr  
 100 105 110

30

Arg Leu Asp Phe His Phe Ser Ser Asp Arg Thr Ala Gly Asp Arg Glu  
 115 120 125

30

Val Gln Gln Ala Ser Leu Met Phe Phe Val Gln Leu Pro Ser Asn Thr  
 130 135 140

35

Thr Trp Thr Leu Lys Val Arg Val Leu Val Leu Gly Pro His Asn Thr  
 145 150 155 160

40

Asn Leu Thr Leu Ala Thr Gln Tyr Leu Leu Glu Val Asp Ala Ser Gly  
 165 170 175

45

Trp His Gln Leu Pro Leu Gly Pro Glu Ala Gln Ala Ala Cys Ser Gln  
 180 185 190

45

Gly His Leu Thr Leu Glu Leu Val Leu Glu Gly Gln Val Ala Gln Ser  
 195 200 205

50

Ser Val Ile Leu Gly Gly Ala Ala His Arg Pro Phe Val Ala Ala Arg  
 210 215 220

55

Val Arg Val Gly Gly Lys His Gln Ile His Arg Arg Gly Ile Asp Cys  
 225 230 235 240

Gln Gly Gly Ser Arg Met Cys Cys Arg Gln Glu Phe Phe Val Asp Phe  
 245 250 255

5 Arg Glu Ile Gly Trp His Asp Trp Ile Ile Gln Pro Glu Gly Tyr Ala  
 260 265 270

10 Met Asn Phe Cys Ile Gly Gln Cys Pro Leu His Ile Ala Gly Met Pro  
 275 280 285

15 Gly Ile Ala Ala Ser Phe His Thr Ala Val Leu Asn Leu Leu Lys Ala  
 290 295 300

20 Asn Thr Ala Ala Gly Thr Thr Gly Gly Ser Xaa Cys Val Pro Thr  
 305 310 315 320

25 Ala Arg Arg Pro Leu Ser Leu Leu Tyr Tyr Asp Arg Asp Ser Asn Ile  
 325 330 335

30 Val Lys Thr Asp Ile Pro Asp Met Val Val Glu Ala Cys Gly Cys Ser  
 340 345 350

### Claims

1. Protein selected from the members of the TGF- $\beta$  superfamily,  
characterized in that the protein is necessarily monomeric due to substitution or deletion of a cysteine which is  
35 responsible for dimer formation.
2. Protein according to claim 1,  
characterized in that the protein is a mature protein or a biologically active part or variant thereof.
3. Protein according to any one of the preceding claims,  
characterized in that the protein contains at least the 7 cysteine region characteristic for the TGF- $\beta$  protein superfamily.
4. Protein according to claim 3,  
characterized in that it contains a consensus sequence according to Formula I: C(Y)<sub>25-29</sub>CYYYC(Y)<sub>25-35</sub>XC  
45 (Y)<sub>27-34</sub>CYC or Formula II: C(Y)<sub>28</sub>CYYYC(Y)<sub>30-32</sub>XC(Y)<sub>31</sub>CYC, wherein C denotes cysteine, Y denotes any amino acid and X denotes any amino acid except cysteine.
5. Protein according to any one of claims 1 to 4,  
characterized in that the protein is a morphogenetic protein.  
50
6. Protein according to any one of the preceding claims,  
characterized in that the protein belongs to the TGF- $\beta$ , BMP, GDF, activin or GDNF family.
7. Protein according to claim 6,  
characterized in that the protein is MP52 (GDF5) or a biologically active part or variant thereof.  
55
8. Protein according to any one of the preceding claims,

characterized in that it comprises the amino acid sequence according to SEQ.ID.NO.2 or a part thereof.

9. Protein according to claim 6,  
characterized in that the protein is MP121 or a biologically active part or variant thereof.  
5
10. Protein according to claim 9,  
characterized in that it comprises the amino acid sequence according to SEQ.ID.NO.4 or a part thereof.  
10
11. Protein according to any one of claims 1 to 10,  
characterized in that the cysteine residue is substituted by an amino acid selected from the group of alanine, serine,  
threonine, leucine, isoleucine, glycine and valine.  
15
12. Protein according to any one of claims 1 to 11,  
characterized in that it contains additional amino acids that facilitate or mediate the transfer and localization of the  
protein in a certain tissue.  
20
13. Nucleic acid,  
characterized in that it encodes a protein according to any one of claims 1 to 12.  
25
14. Nucleic acid according to claim 13,  
characterized in that it is a DNA.  
25
15. Nucleic acid according to claim 13 or 14,  
characterized in that it contains a sequence as shown in SEQ.ID.NO.1 or a fragment thereof.  
30
16. Nucleic acid according to claim 13 or 14,  
characterized in that it contains a sequence as shown in SEQ.ID.NO.3 or a fragment thereof.  
30
17. Nucleic acid according to any one of claims 13 to 16,  
characterized in that it further contains suitable expression control sequences facilitating and/or driving expression  
of the encoded protein.  
35
18. Expression vector,  
characterized in that it contains a nucleic acid according to any one of claims 13 to 17 in a suitable vector system.  
35
19. Expression vector according to claim 18,  
characterized in that the vector system is suitable for prokaryotic expression.  
40
20. Host cell,  
characterized in that it contains a nucleic acid according to any one of claims 13 to 17 or an expression vector  
according to claims 18 or 19 and upon expression of said nucleic acid or vector is able to produce a monomeric  
protein according to any one of claims 1 to 12.  
45
21. Host cell according to claim 20,  
characterized in that it is a prokaryotic host cell.  
45
22. Host cell according to claim 20,  
characterized in that it is an embryonal cell.  
50
23. Pharmaceutical composition,  
characterized in that it contains at least one protein according to any one of claims 1 to 12 or at least one nucleic  
acid according to any one of claims 13 to 17, at least one expression vector according to any one of claims 18 or  
19 or at least one host cell according to claim 20 or 22.  
55
24. Pharmaceutical composition according to claim 23,  
characterized in that the protein and/or nucleic acid are contained in and/or on a biocompatible matrix material.  
55
25. Pharmaceutical composition according to claim 24,

characterized in that the matrix material is biodegradable.

26. Pharmaceutical composition according to claims 24 or 25,  
characterized in that the matrix material is itself osteogenically active.
- 5  
27. Pharmaceutical composition according to any one of claims 23 to 26,  
for the prevention or therapy of diseases for which also the dimeric form of the protein would be indicated.
- 10  
28. Pharmaceutical composition according to claim 27,  
for prevention or therapy of diseases associated with bone and/or cartilage damage or affecting bone and/or cartilage disease or situations in which cartilage and/or bone growth is desirable or for spinal fusion.
- 15  
29. Pharmaceutical composition according to claim 27,  
for prevention or therapy of damaged or diseased tissue associated with connective tissue including tendon and/or ligament, periodontal or dental tissue including dental implants, neural tissue including CNS tissue and neuropahtological situations, tissue of the sensory system, liver, pancreas, cardiac, blood vessel, renal, uterine and thyroid tissue, skin, mucous membranes, endothelium, epithelium, for promotion or induction of nerve growth, tissue regeneration, angiogenesis, wound healing including ulcers, burns, injuries or skin grafts, induction of proliferation of progenitor cells or bone marrow cells, for maintenance of a state of proliferation or differentiation, for treatment or preservation of tissue or cells for organ or tissue transplantation, for integrity of gastrointestinal lining, for treatment of disturbances in fertility, contraception or pregnancy.
- 20  
30. Pharmaceutical composition according to any one of claims 23 to 29 for surgical local application, topical or systemic application.
- 25  
31. Pharmaceutical compostion according to any one of claims 23 to 30  
characterized in that it further contains pharmacologically acceptable auxiliary substances.
- 30  
32. Pharmaceutical composition according to any one of claims 30 or 31,  
characterized in that the composition is injectable.
- 35  
33. Pharmaceutical composition according to anyone of claims 30 to 32,  
characterized in that it is contained in a vehicle that allows to direct and release the composition to a determined site of action.
34. Pharmaceutical composition according to claim 33,  
characterized in that the vehicle is selected from liposomes, nanospheres, larger implantable containers and micropumps.
- 40  
35. Use of a pharmaceutical composition according to any one of claims 23 to 34 for the prevention or treatment of any indications of the dimeric form of the protein.

45

50

55

Fig. 1 A

Name: MP52, dimeric form

Formula	$C_{1184}H_{1844}N_{330}O_{350}S_{22}$
Molecular weight	26994 Dalton
Amino acid composition	238 amino acids
Disulfide bond	7 bonds

## Primary structure





Fig. 1 B





European Patent  
Office

## PARTIAL EUROPEAN SEARCH REPORT

Application Number

which under Rule 45 of the European Patent Convention EP 99 11 5613  
shall be considered, for the purposes of subsequent  
proceedings, as the European search report

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X	HÜSKEN-HINDI, PETRA ET AL: "Monomeric activin A retains high receptor binding affinity but exhibits low biological activity." JOURNAL OF BIOLOGICAL CHEMISTRY, (1994) VOL. 269, NO. 30, PP. 19380-19384, 24 July 1994 (1994-07-24), XP002111996 * the whole document *	1-6, 11, 13, 14, 17, 18, 20	C12N15/12 C07K14/495 A61K38/18
Y	---	7-10, 12, 15, 16, 19, 21-35	
X	AMATAYAKUL-CHANTLER, SUPAVADEE (1) ET AL: "(Ser-77)Transforming growth factor-beta-1: Selective biological activity and receptor binding in mink lung epithelial cells." JOURNAL OF BIOLOGICAL CHEMISTRY, (1994) VOL. 269, NO. 44, PP. 27687-27691, 4 November 1994 (1994-11-04), XP002111995 * the whole document *	1-6, 11, 13, 14, 17-22	
Y	---	7-10, 12, 15, 16, 23-35	TECHNICAL FIELDS SEARCHED (Int.Cl.7)  C07K C12N A61K
	---	-/-	
INCOMPLETE SEARCH			
<p>The Search Division considers that the present application, or one or more of its claims, does/do not comply with the EPC to such an extent that a meaningful search into the state of the art cannot be carried out, or can only be carried out partially, for these claims</p> <p>Claims searched completely:</p> <p>Claims searched incompletely:</p> <p>Claims not searched:</p> <p>Reason for the limitation of the search:</p> <p>Although claim 35 is directed to a method of treatment of the human/animal body (Article 52(4) EPC), the search has been carried out and based on the alleged effects of the composition.</p>			
Place of search	Date of completion of the search	Examiner	
THE HAGUE	10 January 2000	Hix, R	
CATEGORY OF CITED DOCUMENTS		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document			



European Patent  
Office

## PARTIAL EUROPEAN SEARCH REPORT

Application Number

EP 99 11 5613

Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
			TECHNICAL FIELDS SEARCHED (Int.Cl.7)
X	BRUNNER, AMY M. ET AL: "Site-directed mutagenesis of glycosylation sites in the transforming growth factor-beta-1 ( TGF - beta -1) and TGF - beta -2 (414) precursors and of cysteine residues within mature TGF - beta -1: Effects on secretion and bioactivity." MOLECULAR ENDOCRINOLOGY, (1992) VOL. 6, NO. 10, PP. 1691-1700., XP000863262 * the whole document *	1-6, 11, 13, 14, 17, 18, 20	
Y	---	7-10, 12, 15, 16, 19, 21-35	
X	BRUNNER A M ET AL: "SITE-DIRECTED MUTAGENESIS OF CYSTEINE RESIDUES IN THE PRO REGION OF THE TRANSFORMING GROWTH FACTOR BETA-1 PRECURSOR EXPRESSION AND CHARACTERIZATION OF MUTANT PROTEINS." J BIOL CHEM, (1989) 264 (23), 13660-13664., XP000857484 * the whole document *	1, 3-6	
Y	---	1-35	
Y	WO 94 17099 A (CELTRIX PHARMA) 4 August 1994 (1994-08-04) * the whole document *	1-35	
Y	---	1-35	
Y	WO 95 04819 A (BIOPH BIOTECH ENTW PHARM GMBH) 16 February 1995 (1995-02-16) * the whole document *	1-35	
Y	---	1-35	
Y	WO 96 01316 A (BIOPH BIOTECH ENTW PHARM GMBH ;HOETTEN GERTRUD (DE); NEIDHARDT HEL) 18 January 1996 (1996-01-18) * the whole document *	1-35	
Y	---	1-35	
	WO 95 16035 A (GENETICS INST ;HARVARD COLLEGE (US)) 15 June 1995 (1995-06-15) * the whole document *	1-35	
	---	-/-	



European Patent  
Office

## PARTIAL EUROPEAN SEARCH REPORT

Application Number

EP 99 11 5613

Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
			TECHNICAL FIELDS SEARCHED (Int.Cl.7)
Y	EP 0 915 168 A (HOECHST MARION ROUSSEL LTD) 12 May 1999 (1999-05-12) * the whole document * ---	1-35	
Y,D	WO 97 03188 A (BIOPH BIOTECH ENTW PHARM GMBH ;HOETTEN GERTRUD (DE); POHL JENS (DE) 30 January 1997 (1997-01-30) * the whole document *	1-35	
A,D	DAOPIN S ET AL: "CRYSTAL STRUCTURE OF TRANSFORMING GROWTH FACTOR-BETA2: UNUSUAL FOLD FOR THE SUPERFAMILY" SCIENCE, US, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE., vol. 257, page 369-373 XP000857489 ISSN: 0036-8075 * the whole document *		
A,D	M P SCHLUNEGGER ET AL: "An unusual feature revealed by the crystal structure at 2.2 Å resolution of human transforming growth factor-beta 2" NATURE, GB, MACMILLAN JOURNALS LTD. LONDON, vol. 358, no. 358, page 430-434-434 XP002110204 ISSN: 0028-0836 * the whole document *		

**ANNEX TO THE EUROPEAN SEARCH REPORT  
ON EUROPEAN PATENT APPLICATION NO.**

EP 99 11 5613

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on. The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

10-01-2000

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9417099	A	04-08-1994	US 5420243 A AU 697916 B AU 4097797 A AU 685084 B AU 6093294 A CA 2153789 A EP 0791011 A JP 8510443 T US 5658883 A	30-05-1995 22-10-1998 08-01-1998 15-01-1998 15-08-1994 04-08-1994 27-08-1997 05-11-1996 19-08-1997
WO 9504819	A	16-02-1995	DE 4420157 A AU 688362 B AU 7498694 A CA 2169171 A CN 1129013 A CZ 9600357 A EP 0713529 A HU 74271 A JP 9501053 T NZ 271376 A US 5994094 A ZA 9405992 A	23-02-1995 12-03-1998 28-02-1995 16-02-1995 14-08-1996 17-07-1995 29-05-1996 28-11-1996 04-02-1997 24-04-1997 30-11-1999 14-03-1995
WO 9601316	A	18-01-1996	DE 19511243 A AU 2979895 A CN 1151758 A DE 19580745 D JP 10502527 T US 5807713 A ZA 9505444 A	04-01-1996 25-01-1996 11-06-1996 11-03-1999 10-03-1998 15-09-1998 14-02-1996
WO 9516035	A	15-06-1995	AU 689184 B AU 1301395 A CA 2176942 A EP 0733109 A FI 962350 A JP 9506261 T NO 962304 A US 5658882 A	26-03-1998 27-06-1995 15-06-1995 25-09-1996 16-07-1996 24-06-1997 04-06-1996 19-08-1997
EP 0915168	A	12-05-1999	JP 9295945 A AU 2408497 A NO 985041 A CZ 9803449 A WO 9741250 A PL 329610 A	18-11-1997 19-11-1997 29-10-1998 17-03-1999 06-11-1997 29-03-1999

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

**ANNEX TO THE EUROPEAN SEARCH REPORT  
ON EUROPEAN PATENT APPLICATION NO.**

EP 99 11 5613

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

10-01-2000

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9703188 A	30-01-1997	DE 19525416 A	16-01-1997
		AU 6615196 A	10-02-1997
		EP 0837938 A	29-04-1998
		JP 11509097 T	17-08-1999

**DERWENT-ACC-NO:** 2001-228100**DERWENT-WEEK:** 200605

COPYRIGHT 2009 DERWENT INFORMATION LTD

**TITLE:** Novel monomeric protein of transforming growth factor-beta family for prevention or therapy of diseases associated with bone, cartilage damage, promotion of wound healing, has substitution or deletion of cysteine

**INVENTOR:** BECHTOLD R; HOETTEN G ; HOTTEN G ; POHL J

**PATENT-ASSIGNEE:** HYGENE AG [HYGEN] , HYGENE AG C/O MAEDER & BAUMGARTNER TREUH [HYGEN]

**PRIORITY-DATA:** 1999EP-115613 (August 6, 1999)**PATENT-FAMILY:**

<b>PUB-NO</b>	<b>PUB-DATE</b>	<b>LANGUAGE</b>
EP 1074620 A1	February 7, 2001	EN
WO 0111041 A1	February 15, 2001	EN
AU 200069927 A	March 5, 2001	EN
EP 1198570 A1	April 24, 2002	EN
ZA 200201032 A	December 24, 2002	EN
JP 2003506086 W	February 18, 2003	JA
NZ 517125 A	August 29, 2003	EN
EP 1198570 B1	July 20, 2005	EN
AU 782481 B2	August 4, 2005	EN
DE 60021388 E	August 25, 2005	DE
US 6972321 B1	December 6, 2005	EN
ES 2242630 T3	November 16, 2005	ES
US 20050282255 A1	December 22, 2005	EN
DE 60021388 T2	January 5, 2006	DE

**DESIGNATED-STATES:** AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK L R LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TZ UG ZW AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI L T LU LV MC MK NL PT RO SE SI AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

**APPLICATION-DATA:**

<b>PUB-NO</b>	<b>APPL-DESCRIPTOR</b>	<b>APPL-NO</b>	<b>APPL-DATE</b>
EP 1074620A1	N/A	1999EP- 115613	August 6, 1999
AU 200069927A	N/A	2000AU- 069927	August 4, 2000
AU 782481B2	N/A	2000AU- 069927	August 4, 2000
DE 60021388E	N/A	2000DE- 621388	August 4, 2000
DE 60021388T2	N/A	2000DE- 621388	August 4, 2000
EP 1198570A1	N/A	2000EP- 958383	August 4, 2000
EP 1198570B1	N/A	2000EP- 958383	August 4, 2000
NZ 517125A	N/A	2000NZ- 517125	August 4, 2000
WO2001011041A1	N/A	2000WO- EP07600	August 4, 2000

EP 1198570A1	N/A	2000WO- EP07600	August 4, 2000
JP2003506086W	N/A	2000WO- EP07600	August 4, 2000
NZ 517125A	N/A	2000WO- EP07600	August 4, 2000
EP 1198570B1	N/A	2000WO- EP07600	August 4, 2000
DE 60021388E	N/A	2000WO- EP07600	August 4, 2000
US 6972321B1	N/A	2000WO- EP07600	August 4, 2000
DE 60021388T2	N/A	2000WO- EP07600	August 4, 2000
JP2003506086W	N/A	2001JP- 515827	August 4, 2000
US 6972321B1	N/A	2002US- 048458	February 6, 2002
ZA 200201032A	N/A	2002ZA- 001032	February 6, 2002
US20050282255A1	Based on	2005US- 191072	July 28, 2005

**INT-CL-CURRENT:**

<b>TYPE</b>	<b>IPC</b>	<b>DATE</b>
CIPP	C12N15/09	20060101
CIPS	A61K35/76	20060101
CIPS	A61K38/18	20060101
CIPS	A61K38/18	20060101
CIPS	A61K38/22	20060101
CIPS	A61K47/46	20060101
CIPS	A61K48/00	20060101
CIPS	A61K9/10	20060101

CIPS	A61K9/127 20060101
CIPS	A61K9/50 20060101
CIPS	A61L27/00 20060101
CIPS	A61P1/02 20060101
CIPS	A61P1/04 20060101
CIPS	A61P15/00 20060101
CIPS	A61P17/02 20060101
CIPS	A61P19/08 20060101
CIPS	A61P21/00 20060101
CIPS	A61P25/00 20060101
CIPS	A61P43/00 20060101
CIPS	C07K14/475 20060101
CIPS	C07K14/495 20060101
CIPS	C07K14/495 20060101
CIPS	C07K14/495 20060101
CIPS	C07K14/575 20060101
CIPS	C12N1/21 20060101
CIPS	C12N15/12 20060101
CIPS	C12N15/12 20060101
CIPS	C12N5/10 20060101

**RELATED-ACC-NO:** 2005-607918

**ABSTRACTED-PUB-NO:** EP 1074620 A1

**BASIC-ABSTRACT:**

NOVELTY - A protein (I) selected from the members of the transforming growth factor-beta (TGF-beta) superfamily, which is monomeric due to substitution or deletion of a cysteine which is responsible for dimer formation, is new.

DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

- (1) nucleic acid (II) encoding (I);
- (2) expression vector (III) containing (II) in a suitable vector system;
- (3) host cell (IV) containing (III) capable of producing (I); and
- (4) a pharmaceutical composition (V) containing (I), (II), (III) or (IV).

Gene therapy. No supporting data is given.

USE - (V) is useful for the prevention or therapy of diseases for which also the dimeric form of the protein would be indicated. Diseases treatable include diseases associated with bone and/or cartilage damage or affecting bone and/or cartilage disease or situations in which cartilage and/or bone growth is desirable, for spinal fusion, for damaged or diseased tissue associated with connective tissue including tendon and/or ligament, periodontal or dental tissue including dental implants, neural tissue including CNS tissue and neuropathological situations, tissue of the sensory system, liver, pancreas, cardiac, blood vessel, renal, uterine and thyroid tissue, skin, mucous membrane, endothelium, epithelium, for promotion or induction of nerve growth, tissue regeneration, angiogenesis, wound healing including ulcers, burns, injuries or skin grafts, induction of proliferation of progenitor cells or bone marrow cells, for maintenance of a state of proliferation or differentiation, for treatment or preservation of tissue or cells for organ or tissue transplantation, for integrity of gastrointestinal lining and for treatment of disturbances in fertility, contraception or pregnancy (all claimed).

**EQUIVALENT-ABSTRACTS:**

BIOTECHNOLOGY

Preferred Protein: (I) is a mature protein or a biologically active part or its variant and contains at least 7 cysteine region characteristic for the TGF-beta protein superfamily. (I) contains a consensus sequence of formula Cys-(Y)(25-29)-Cys-Y-Y-Cys-(Y)(25-35)-X-Cys-(Y)(27-34)-Cys-Y-Cys or Cys-(Y)28-Cys-Y-Y-Cys-(Y)(30-32)-X-Cys-(Y)31-Cys-Y-Cys,

Y = any amino acid

X = amino acid except cysteine

The protein is a morphogenetic protein belonging to the TGF-beta, bone morphogenic protein (BMP), growth differentiation factor (GDF), activin or glial cell line-derived neurotrophic factor (GDNF) family. In (I) the cysteine residue is substituted by alanine, serine, threonine, leucine, isoleucine, glycine or valine and contains additional amino acids that facilitate or mediate the transfer and localization of the protein in a certain tissue.

Preferred Nucleic Acid: (II) is DNA and further contains suitable expression control sequences facilitating and/or driving expression of the encoded protein. The vector system containing (II) is suitable for prokaryotic expression.

Preferred Cell: (IV) is a prokaryotic cell, preferably a embryonal cell.

Preferred Composition: (V) contains (I) and/or (II) in and/or on a biocompatible, biodegradable matrix material. The material is itself osteogenically active. (V) is an injectable composition or is a vehicle such as liposomes, nanospheres, larger implantable containers or micropumps that allows to direct and release the composition to a determined site of action.

Preparation: The monomeric protein can be prepared by

standard recombinant methods, in particular by expression in prokaryotes.

(V) is suitable for surgical local application, topical or systemic application (claimed). Dosage not specified.

#### SPECIFIC PROTEINS

(I) is selected from MP52 (GDF5) and MP121 (their biologically active parts or variants), comprising a sequence of 501 and 352 amino acids, respectively, encoded by a DNA sequence of 2703 and 2272 base pair defined in the specification (claimed).

None given.

**TITLE-TERMS:** NOVEL MONOMERIC PROTEIN TRANSFORM GROWTH FACTOR BETA FAMILY PREVENT THERAPEUTIC DISEASE ASSOCIATE BONE CARTILAGE DAMAGE PROMOTE WOUND HEAL SUBSTITUTE DELETE CYSTEINE

**DERWENT-CLASS:** B04 D16 P34

**CPI-CODES:** B04-E02B; B04-E04; B04-E08; B04-F0100E;  
B04-H01; B04-N02B; B14-F01; B14-F02;  
B14-G02C; B14-J01; B14-J05; B14-N01;  
B14-N06; B14-N07; B14-N12; B14-N16; B14-  
N17; B14-P01; B14-P02; B14-S03; D05-  
C12; D05-H12B2; D05-H12D5; D05-H12E;  
D05-H14; D05-H17;

**CHEMICAL-CODES:** Chemical Indexing M1 \*01\* Fragmentation  
Code M423 M710 N135 P446 P519 P520 P624  
P714 P721 P723 P923 P941 P942 P943 Q233  
Specific Compounds RA00NS Registry  
Numbers 93605

Chemical Indexing M1 \*02\* Fragmentation  
Code M423 M710 N135 P446 P519 P520 P624  
P714 P721 P723 P923 P941 P942 P943 Q233  
Specific Compounds RA00GT Registry  
Numbers 200757 200799

Chemical Indexing M1 \*03\* Fragmentation  
Code M423 M710 P446 P519 P520 P624 P714  
P721 P723 P923 P941 P942 P943 Q233  
Specific Compounds RA0365 Registry  
Numbers 109233

Chemical Indexing M1 \*04\* Fragmentation  
Code M423 M710 P446 P519 P520 P624 P714  
P721 P723 P923 P941 P942 P943 Q233  
Specific Compounds RA1K5Q Registry  
Numbers 274369

Chemical Indexing M1 \*05\* Fragmentation  
Code M423 M710 P446 P519 P520 P624 P714  
P721 P723 P923 P941 P942 P943 Q233  
Specific Compounds RA03QY Registry  
Numbers 86535

**SECONDARY-ACC-NO:**

**CPI Secondary Accession Numbers:** 2001-068236